483
Comparative Biosciences, IncFDA 483 - Comparative Biosciences, Inc - July 30, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Comparative Biosciences, Inc. in Sunnyvale, CA, revealed significant Good Laboratory Practice (GLP) deficiencies. Observations included failures to properly document protocol changes, provide adequate separate laboratory space for BSL-2 studies, and ensure equipment was adequately inspected, cleaned, and maintained with appropriate records. These issues compromise study integrity and biosafety.
Open in Dashboard
ID · 17ad7641-5177-4b8d-8995-fa0ea23668a8